RxDoctor Payments Data

Zynnia Zafra, MD

Psychiatry · Tuscaloosa, ALNPI 1124122718

Payments from drug & device makers

$3,458in general payments, 2019–2025

Across 116 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$943
  • Otsuka America Pharmaceutical, Inc.$609
  • Teva Pharmaceuticals USA, Inc.$362
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$354
  • AbbVie$294
  • Neurocrine Biosciences, Inc.$285
  • plus $611 from 6 others

What the payments were for

  • Food & beverage$3,44099%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,458 in reported general payments places this provider in the 75th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$13,192
Medicare patients
45
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole21$62,698
Invega SustennaPaliperidone Palmitate16$40,708
RexultiBrexpiprazole12$14,011
Chlorpromazine Hcl25$9,206
JardianceEmpagliflozin19$5,646
Divalproex Sodium46$4,348
Haloperidol Decanoate42$4,304
Clozapine51$2,390
Haloperidol37$1,935
Divalproex Sodium ErDivalproex Sodium54$1,907
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,803
Olanzapine33$1,329
Aripiprazole31$1,294
Quetiapine Fumarate64$1,124
Benztropine Mesylate42$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$609$76,70933 claims
Johnson & JohnsonInvega Sustenna$124$40,70816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →